Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO XR versus SITAGLIPTIN AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO XR versus SITAGLIPTIN AND METFORMIN HYDROCHLORIDE.
JENTADUETO XR vs SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
Oral, initial dose based on prior therapy and glycemic control: 50 mg sitagliptin / 500 mg metformin twice daily or 50 mg sitagliptin / 1000 mg metformin twice daily. Max sitagliptin 100 mg/day, metformin 2000 mg/day.
None Documented
None Documented
Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Metformin: Terminal half-life ~6.2 hours (plasma), but prolonged to ~17.6 hours in renal impairment; clinical context: dosing interval adjusted for CrCl. Sitagliptin: Terminal half-life ~12.4 hours, allows once-daily dosing.
Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Metformin: 90% renal unchanged (active tubular secretion), 10% fecal. Sitagliptin: 87% renal (active tubular secretion), 13% fecal (biliary excretion minimal for sitagliptin, but fecal includes unabsorbed drug).
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor